Enhancing vaccine half-life as a novel strategy for improving immune response durability of subunit vaccines
PLOS Pathogens · 2025
DOI: 10.1371/journal.ppat.1012845 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Pathogens, 2025. Verfasst von Zhaoling Shen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS) and Shanghai Institute of Infectious Disease and Biosecurity, Shanghai Frontiers Science …. Hauptthemen laut MEDLINE: COVID-19 Vaccines, SARS-CoV-2, Vaccines, Subunit, COVID-19. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Science and Technology of China, National Natural Science Foundation of China, Science and Technology Commission of Shanghai Municipality.
Abstract (Originalsprache)
Vaccines are widely regarded as one of the most effective strategies for combating infectious diseases. However, significant challenges remain, such as insufficient antibody levels, limited protection against rapidly evolving variants, and poor immune durability, particularly in subunit vaccines, likely due to their short in vivo exposure. Recent advances in extending the half-life of protein therapeutics have shown promise in improving drug efficacy, yet whether increasing in vivo persistence can enhance the efficacy of subunit vaccines remains underexplored. In this study, we developed two trimeric SARS-CoV-2 subunit vaccines with distinct pharmacokinetic profiles to evaluate the impact of vaccine persistence on immune efficacy. A self-assembling trimeric subunit vaccine (RBD-HR/trimer) was designed, followed by an extended-persistence variant (RBD-sFc-HR/trimer) incorporating a soluble monomeric IgG1 fragment crystallizable. We demonstrated that RBD-sFc-HR/trimer elicited more robust and higher levels of neutralizing antibodies, with potent and broad neutralization activity against multiple SARS-CoV-2 variants. Notably, RBD-sFc-HR/trimer induced a durable immune response, significantly increasing the number of memory B cells and T cells. This study provides critical insights for designing vaccines that achieve potent and long-lasting immune responses against infectious diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS) and Shanghai Institute of Infectious Disease and Biosecurity, Shanghai Frontiers Science Center of Pathogenic Microorganisms and Infection, School of Basic Med…
- College of Life Sciences, Hebei Agricultural University, Baoding, China.
- Fosun Diagnostics (Shanghai) Co., Ltd, Shanghai, China.
- Shanghai Engineering Research Center for Synthetic Immunology, Shanghai, China.
ORCID-Profile: Tianlei Ying
Förderung
- Ministry of Science and Technology of China
- National Natural Science Foundation of China
- Science and Technology Commission of Shanghai Municipality
- Shanghai Municipal Health Commission
- the Ministry of Science and Technology of China
Zitieren
APA
Shen, Z., Li, C., Song, W., Liu, L., Kong, Y., Huang, A., Bao, Q., Ying, T., & Wu, Y. (2025). Enhancing vaccine half-life as a novel strategy for improving immune response durability of subunit vaccines. PLOS Pathogens. https://doi.org/10.1371/journal.ppat.1012845
Vancouver
Shen Z, Li C, Song W, Liu L, Kong Y, Huang A, et al. Enhancing vaccine half-life as a novel strategy for improving immune response durability of subunit vaccines. PLOS Pathogens. 2025. doi:10.1371/journal.ppat.1012845
BibTeX
@article{Shen2025,
author = {Shen, Zhaoling and Li, Cheng and Song, Wenping and Liu, Litong and Kong, Yu and Huang, Ailing and Bao, Qingui and Ying, Tianlei and Wu, Yanling},
title = {Enhancing vaccine half-life as a novel strategy for improving immune response durability of subunit vaccines},
journal = {PLOS Pathogens},
year = {2025},
doi = {10.1371/journal.ppat.1012845}
}
EUVIMED